CN103354745B - 基于粘土和蜂花粉的组合物、其制备方法、其营养用途和治疗用途 - Google Patents
基于粘土和蜂花粉的组合物、其制备方法、其营养用途和治疗用途 Download PDFInfo
- Publication number
- CN103354745B CN103354745B CN201180067389.6A CN201180067389A CN103354745B CN 103354745 B CN103354745 B CN 103354745B CN 201180067389 A CN201180067389 A CN 201180067389A CN 103354745 B CN103354745 B CN 103354745B
- Authority
- CN
- China
- Prior art keywords
- clay
- bee pollen
- compound
- pollen
- bee
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004927 clay Substances 0.000 title claims abstract description 123
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims description 27
- 230000001225 therapeutic effect Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 230000036541 health Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 17
- 241000256844 Apis mellifera Species 0.000 claims description 14
- 239000001828 Gelatine Substances 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 206010016256 fatigue Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052900 illite Inorganic materials 0.000 claims description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052622 kaolinite Inorganic materials 0.000 claims description 6
- VGIBGUSAECPPNB-UHFFFAOYSA-L nonaaluminum;magnesium;tripotassium;1,3-dioxido-2,4,5-trioxa-1,3-disilabicyclo[1.1.1]pentane;iron(2+);oxygen(2-);fluoride;hydroxide Chemical compound [OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[F-].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[K+].[K+].[K+].[Fe+2].O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2 VGIBGUSAECPPNB-UHFFFAOYSA-L 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000003746 feather Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000009245 menopause Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 208000034657 Convalescence Diseases 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 206010036968 Prostatic pain Diseases 0.000 claims description 3
- 229910001919 chlorite Inorganic materials 0.000 claims description 3
- 229910052619 chlorite group Inorganic materials 0.000 claims description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000013507 chronic prostatitis Diseases 0.000 claims description 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000025844 Prostatic disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 description 20
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 229960000907 methylthioninium chloride Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 241000233866 Fungi Species 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 125000001475 halogen functional group Chemical group 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960000892 attapulgite Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002734 clay mineral Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052625 palygorskite Inorganic materials 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 239000004113 Sepiolite Substances 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229910052631 glauconite Inorganic materials 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 229910052624 sepiolite Inorganic materials 0.000 description 2
- 235000019355 sepiolite Nutrition 0.000 description 2
- -1 silicate hydrates Chemical class 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000004957 Castanea mollissima Species 0.000 description 1
- 235000018244 Castanea mollissima Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000028508 Cistus creticus Species 0.000 description 1
- 235000013306 Cistus creticus Nutrition 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241001163113 Photinia glabra Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 229940038481 bee pollen Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000008695 cernilton Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910001753 sapphirine Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
本发明涉及蜂花粉和粘土的复合物、其制备方法以及其治疗用途,或作为人类卫生保健或动物卫生保健中的食品补充剂、功能性食品。
Description
背景技术
花粉是花朵的雄性授粉元素且是蜜蜂的蛋白质的唯一来源。花粉通过蜜蜂从雄花采收以便将花粉运输到小球形式的蜂巢中。因此,通常花粉由术语“蜂花粉”来表示以区分蜜蜂传送的花粉与风传送的花粉。因而通过蜜蜂采收的花粉富含益生元,例如,酶和酵母菌,其收纳在蜜蜂的唾液中。
由于花粉内在的结构,故花粉在人类营养中还是极其引人注目的食品,这是因为新鲜花粉包括蛋白质(±25%)、酶和辅酶(包括淀粉酶、转化酶、磷酸酶、转移酶)、大量的维生素(全部B族维生素、维生素C、维生素D、维生素A原、维生素K、维生素E、芸香苷)、微量元素(如钙、镁、磷、铁、铜、锰等)、矿物质(铜、铁、锰、磷、硅、硫)、甾醇、黄酮、色素、雌激素物质、生长因子、硒、糖类、脂类等,该蛋白质特别包括人体必需的氨基酸,这些氨基酸包括人体不能合成的氨基酸(苯丙氨酸、色氨酸、酪氨酸、赖氨酸、苏氨酸、蛋氨酸、半胱氨酸、亮氨酸、异亮氨酸、缬氨酸)。由于花粉重要的营养功效,故花粉具有扩大代谢的作用且对于最佳的大众健康赋予活力。
例如,花粉中富含的植物雌激素(如,异黄酮)可以预防心血管疾病、骨质疏松症、前列腺癌。花粉中异黄酮的存在还表明在体液流动上的有益效果。
更具体地,对骨质疏松症的效果还通过大鼠口服花粉引起的骨刺激得到支持(Yamaguchi等,J.of Health Science,2006年,第43页至第49页)。
多个研究也已经表明花粉(Cernilton标准机械采收的黑麦的花粉提取物)在治疗前列腺良性增生中的功效(Wilt等,Cochrane Database Syst.Rev.2000(2)CD001042)。还已经报道了不同的蜂花粉提取物通过细胞凋亡对某些类型的前列腺癌的作用(Wu等,Phytother.Res.2007年,21(11),第1087页至第1091页)。
Eraslan等(Ecotoxicol.Environ.Saf 2009年,72(3),第931页至第937页)已经描述了在肝素剂施用期间蜂花粉的保护效果,这表明蜂花粉在肝脏以及通常新陈代谢上的有益效果。
通过施用基于花粉的组合物,已经观察到更年期症状的改善(Georgiev等,Med.Gen.Med.2004年,6(4),第46页)。
还认识到花粉恢复神经平衡,以及改善失眠和疲劳症状。还探索了花粉用于刺激胃功能(对食欲、消化和消化运输的调节具有促进作用)和循环失调。因此,花粉有助于血液再生,特别是通过增加血红蛋白水平的血液再生从而特别适合贫血人群或贫血儿童;通过组合动脉-毛细血管-静脉的抗性和弹性试剂(芸香苷、维生素C、维生素E和蛋氨酸),花粉还调节血液凝固(抗凝血酶)且有助于心血管保护。维生素A的存在还表明花粉在预防或治疗眼部疾病上的有益效果。
除了花粉这些固有的好处外,如果蜂花粉完整地在肠内运送,则多数蜂花粉允许施用有助于对于健康所必需的肠道菌群的乳酸酶。
然而,新鲜的花粉是不稳定的。因此,如今花粉基本上以两种形式销售。
在有利于花粉分散的干燥形式(寿命长、易于使用)中,然而花粉丧失其显著的抗菌性能的主要部分。
冷冻形式可以维持花粉的性能,但由于必须维持冷藏链,故使患者的购买和服用不太方便。
无论是干燥或冷冻,花粉以颗粒形式出现,这具有其他的缺点,例如对于最终的消费者以及对于进行临床研究,难于观察到真实的剂量且可能被评估为令人不愉快的口感。
发明内容
因此,期望得到一种允许施用优选天然形式的蜂花粉的剂型,其中该剂型保持了新鲜蜂花粉的性能,特别是上文提到的营养性能和心理属性,同时满足稳定和易于使用的需求。
本发明人现已证实蜂花粉和粘土之间的协同作用,该协同作用可稳定配制和保存蜂花粉、或者甚至优化蜂花粉的营养性能、生理性能和治疗性能,促进蜂花粉的保存、施用、投放市场、消费和同化、以及进行临床研究。
因此,本发明涉及蜂花粉和粘土的组合。所述组合允许在满足上述需求的同时配制蜂花粉。
由于粘土的吸收性能、保持性能和吸附性能,故由此形成的组合具有密切相关的结构且在本文也可称为“蜂花粉/粘土复合物”。
根据本发明的蜂花粉/粘土复合物还可被定义为源于任意植物物种的蜂花粉结合在硅酸盐层状结构上所产生的任何稳定的物质。
在本发明的含义内,“蜂花粉”指由蜜蜂采收后取样的花粉。该蜂花粉可利用任意手段采收,尤其在蜂花粉进入蜂房之前(通过采粉器)采收或根据惯用的方法在蜂房中采收。
术语“蜂花粉”指可以维持新鲜花粉的生物活性的任何形式的花粉。因此,蜂花粉包括新鲜蜂花粉,还尤其包括预先进行冷冻的蜂花粉。
在本发明的范围内,蜂花粉可起源于各种植物品种和种类,且不限于特定的花。因此,可提到的有由黑麦、玉米、向日葵、岩蔷薇、板栗、猕猴桃、柳树、罂粟、薰衣草、石楠等获取的蜂花粉。
蜂花粉,尤其是冷冻的蜂花粉,例如可从Pollenergie处购买。
尤其是根据来源植物的性质以及根据采收时期或还根据采收方法,蜂花粉还可以是可变的组合物。
因此,适合于本发明的新鲜蜂花粉通常包含5%至36%的水和64%至95%的干物质,其中干物质包括:
-2.5%至3.8%的矿物盐;
-4.2%至19.8%的脂类;
-8%至30%的白蛋白;
-5%至7%的淀粉;
-维生素;
-生长因子;
-叶酸;
-多酚;
-植物甾醇;
-酶和酵母。
“粘土”是指包含粘土矿物的材料,例如硅酸盐水合物,尤其是硅酸铝或硅酸镁。具有包括一个或多个层的层状结构的层状硅酸盐是特别优选的。
基于层的厚度和结构,根据Jozja分类法,粘土分为四类:
i)矿物:厚度大约为这是高岭石类(高岭石、埃洛石等);
ii)矿物:厚度大约为这是伊利石类(伊利石、海绿石);
iii)矿物:厚度大约为这是蒙脱石类(蒙脱石、膨润土、粘土等);
iv)纤维状矿物:层的厚度是可变的,该矿物被称作绿泥石或纤维状矿物(海泡石、绿坡缕石等)。
因此,根据本发明的术语“粘土”指这四种类型的粘土。对于粘土矿物,可尤其提到伊利石、绿泥石、海绿石、高岭石、绿坡缕石、海泡石和蒙脱石。对于粘土,尤其优选的是高岭土、伊利石、蒙脱石、绿坡缕石,且特别是蒙脱石。
粘土矿物具有特殊的理化性质,如负电荷,该负电荷必须由位于层间的阳离子来补偿。阳离子交换容量(CEC)针对粘土物质的类型是特定的。CEC被定义为用于替代补偿阳离子的用以补偿100克粘土的负电荷的一价阳离子的数量或等量阳离子。通过将显色剂(阳离子)逐步加入水悬浮液直到饱和来确定CEC。CEC通常以毫克当量/100克表示。
层结构还导致粘土材料的特定性能,即在水的存在下溶胀。该溶胀相当于水分子渗入层间,且可以是结晶类型(在水存在下带电的层和阳离子之间的静电引力破坏)或者渗透类型(在大量的水的存在下形成凝胶然后形成悬浮液)。
因此,在上述不同类型的具有CEC和特定吸收容量的粘土中,蒙脱石的CEC在80毫克当量/100克和150毫克当量/100克之间,且吸收容量(通过干粘土和湿粘土之间的重量差而测量的性能)大约为20%。
根据本发明的复合物通常包括:
-4%至90%的蜂花粉,和
-10%至96%的粘土。
百分比按重量计。
更优选地,根据本发明的复合物包括:
-20%至40%的蜂花粉,和
-60%至80%的粘土,
且更具体地,
-30%至35%的蜂花粉,和
-65%至70%的粘土。
利用根据本发明的复合物,可以维持以保持其生物活性的形式存在的蜂花粉。因此,利用根据本发明的复合物,可以维持足够的湿度以保存酶和酵母,同时出乎意料地得到由此所配制的蜂花粉的稳定性。
根据本发明的复合物有利地具有小于500μm的粒径、小于15%的湿度、和/或小于0.75的水活度(wa)。
根据另一目的,本发明还涉及用于制备根据本发明的复合物的方法。因此,所述方法包含混合蜂花粉和粘土的步骤。
该混合有利地通过在环境空气中搅拌而实现。通常,制备该复合物要确保在制备混合物(全部干物质)期间不能有水(液体形式)的污染。
通过具有500μm筛孔的筛子而得到所期望的粒径。
根据本发明,复合物具有与所使用的蜂花粉以及粘土潜在地相关的特定的生物活性;反过来,粘土具有固有的性质,如保护肠粘膜的作用、其抗酸性和抗碱性的功效、其粘合性能和可以排放气体和毒素。
本文的“生物活性”是指在消耗它们的主体中由所述复合物产生的营养上或生理上的效果,例如治疗效果。
蜂花粉作为营养素的浓缩来源的营养性能、以及在骨质疏松、心血管疾病、肝脏和代谢紊乱、循环失调、更年期症状、神经系统障碍、肠胃系统障碍、关节障碍、眼部疾病、泌尿功能失调、疲劳、前列腺障碍(如前列腺的良性肥大、慢性前列腺炎、前列腺痛和前列腺癌)上的生理特性,由于蜂花粉的这些特点而知名。由于蜂花粉的性质,蜂花粉还可用于营养疾病、皮肤病和化妆致皮肤病(包括附肢(指甲、毛发))、无力和易疲劳、恢复期和术后、体液-电解质失衡和身体状况的改善。
因此,发明人已经示出了通过蜂花粉/粘土复合物施加的协同作用,特别是复合物的吸收容量和吸收速率、保持性能、吸附容量、乳酸酶的装载量及对微生物的影响,其总体大于各个组分的单个效果的总和。
这些性质的增强作用能够考虑改善蜂花粉和/或粘土的效果,从而在根据本发明的复合物的范围内施用。
因此,根据本发明的复合物可用于治疗或者可用于人类和/或动物的营养物,以及用于预防和/或治疗的用途。
因此,本发明涉及一种包括根据本发明的复合物的药物组合物。
因此,所述组合物可显著地形成欧盟指令(European Directive)2001/83/EC意义上的药物性能。
所述组合物还可包括一种或多种药学上可接受的赋形剂。
根据本发明的药物组合物可具有适于通过口途径、舌下途径、局部途径、区域(local)途径、气管内途径、鼻内途径或直肠途径来给药的形式。
该药物组合物可特别地以溶液或多剂量瓶的形式存在,或者以未包衣药片或包衣药片、糖衣丸、胶囊、软明胶胶囊和硬明胶胶囊、颗粒、丸、药片、粉末、栓剂或直肠用胶囊、溶液或悬浮液、或其它霜剂、凝胶、软膏、药膏等形式存在。
适合于这样施用的药学上可接受的赋形剂可尤其选自纤维素衍生物或微晶纤维素衍生物、碱土金属碳酸盐、磷酸镁、淀粉、改性淀粉、固体形式的乳糖、可可脂或聚乙二醇硬脂酸酯、水、水溶液、盐水、等渗溶液等。
更具体地,本发明旨在提供包含蜂花粉/粘土复合物的明胶胶囊。
可按照惯例执行配制这样的明胶胶囊。
优选地,所述组合物包含有效量的根据本发明的复合物。
根据治疗指示和给药途径,以及根据主体的年龄和体重,剂量可在宽范围(0.5mg至1000mg)内变化。
较高剂量或较低剂量适合的特殊情况是:这类剂量未偏离本发明的范围。根据惯例,根据施用方法、所述主体的体重或响应确定对于每个患者的合适剂量。
本发明还涉及一种用于预防和/或预防下列疾病的根据本发明的复合物:骨质疏松、心血管疾病、肝脏和代谢紊乱、循环失调、更年期症状、神经系统障碍、肠胃系统障碍、关节障碍、眼部疾病、泌尿功能失调、疲劳、前列腺障碍(如前列腺的良性肥大、慢性前列腺炎、前列腺痛和前列腺癌等)、营养疾病、皮肤疾病、化妆致皮肤病、无力和易疲劳、恢复期和术后、体液-电解质的失衡、和身体状况的改善。
根据另一目的,本发明还涉及根据本发明的复合物作为营养素的用途。
“作为营养素的用途”指根据本发明的复合物用作或用于功能性食品(功能食品)或食品补充剂的用途。
功能性食品或营养药通常被定义为常规食品,或者具有常规食品的外观,常规食品属于正常摄取食物,且具有提供了超出其一般营养功能的有益生理效果或者减少慢性疾病风险的特征。
因而,所述补充剂可形成欧盟指令2002/46/EC意义上的食品补充剂。
实际上,根据本发明的复合物形成食品,该食品的用途在于,通过形成营养素(尤其上文提到的维生素B、维生素原A和维生素C、维生素D和维生素E、以及矿物质)的浓缩来源以及具有营养效果和/或生理效果的作为组合的其它上述物质,来完成正常的饮食。
因此,本发明涉及一种食品组合物,例如包含根据本发明的蜂花粉/粘土复合物的功能性食品或食品补充剂。
所述食品补充剂有利地配制成剂量形式,即,以欧洲指令2002/46/EC定义的剂量形式,例如,“明胶胶囊、锭剂、片剂、丸剂和其他类似的形式、以及香粉、液体针剂、设有滴管和用于以少量单位服用的其他类似于液体制剂或粉末制剂的形式的容量瓶”。
根据本发明的食品补充剂有利地是明胶胶囊的形式。该食品补充剂还可包含常规的食品赋形剂。
本发明还涉及包含根据本发明的蜂花粉/粘土与另外的活性剂的组合。
实际上,根据本发明的蜂花粉/粘土复合物可用于增强所述制剂和复合物的普通活性,或者作为用于改善配制、施用和/或生物利用率或者还用于减少该复合物的副作用的载体。
因此,本发明还涉及一种包含根据本发明的粘土和蜂花粉的组合作为载体的药物。
附图说明
图1至图6分别示出了与基于每种根据本发明的蜂花粉/粘土复合物的成分的性质估算的值比较,根据本发明的蜂花粉/粘土复合物的乳酸菌和真菌的装载量以及吸收容量、吸收速率、保持力和吸附容量。
具体实施方式
下列实施例示出了本发明,但不限制本发明。所使用的初始产品为已知的产品或根据已知的操作步骤制备的产品。
百分比以重量百分比表示,除非另有说明。
实施例1:蜂花粉/粘土复合物的制备
硬件:
精密电子天平-Mettler Toledo PG803
搅拌器-IKA Labotechnik Eurostar
250mL的玻璃烧杯-Bomex
匙形的弯曲刮刀,不锈钢18/8-Labo-moderne
原材料供应商:
氮气冷冻的向日葵蜂花粉:Pollenergie,La Grabère–47450,Saint-Hilaire deLusignan;Tel.05 53 68 11 11-Fax.05 53 68 11 12。
蒙脱石粘土:Argiletz,14 route d′Echampeau-77 440 Liz-sur-Ourcq,Tel.0160 61 20 88-Fax.01 60 61 27 39。
制备9种不同配方(%)的组合:
-粘土100/蜂花粉0,
-粘土90/蜂花粉10,
-粘土80/蜂花粉20,
-粘土66.66/蜂花粉33.33,
-粘土50/蜂花粉50,
-粘土33.33/蜂花粉66.66,
-粘土20/蜂花粉80,
-粘土10/蜂花粉90,
-粘土0/蜂花粉100。
在下文中详细描述了说明性的操作步骤:
为了制备150g的蜂花粉/粘土复合物:每种组分的比例为:66.66%的粘土与33.33%的蜂花粉。
-在250mL烧杯中称量100g的粘土;
-在250mL烧杯中称量50g的冷冻蜂花粉;
-优选地干燥搅拌器的部件以便避免复合物的水合作用;
-混合粘土;
-添加蜂花粉且保持混合30秒。
通过500μm筛孔的筛子筛分,得到所需的粒径。
如果建立在最大效果的10%处的阈值,则确定窗口,在该窗口中复合物具有显著的效果,该复合物对应于:
-蜂花粉:4.5%至87.6%,优选33.33%;
-粘土:95.5%至12.4%,优选66.66%。
表征了由此制备的复合物。这些复合物的产品特征汇总在下表中:
进行用于评估组分的协同作用对复合物的功效的测试。具有66.66%的粘土和33.33%的蜂花粉的组合具有最大功效。
实施例2:实施例1的蜂花粉/粘土复合物的性质的研究
对总乳酸菌计数
在蜂花粉中含有的乳酸菌的种类没有清楚地进行鉴别。因此,使用可以计数大多数种类的乳酸菌的测试(ISO15214标准)。
■成分(粘土和蜂花粉)的乳酸菌:为了评估蜂花粉/粘土复合物的优点,首先估算每种成分中的任一数量的乳酸菌。
粘土有0CFU/g。
蜂花粉有152CFU/g。
■蜂花粉/粘土复合物中的乳酸菌:通过对蜂花粉和粘土进行特定计数,从而估算该复合物(通过考虑复合物中的粘土和蜂花粉的比例)中的乳酸菌的数量(图1)。
因此,根据本发明的估算,蜂花粉/粘土复合物应当包含50.7CFU/g。
目前,测量示出蜂花粉/粘土复合物含有481CFU/g。
复合物具有的乳酸菌比估算值多9.5倍。
真菌的生长
真菌是模糊的土名,这是指来自霉菌领域的某些丝状显微微生物。真菌存在数千个不同的种类。它们是在长度上可达到35米的多细胞有机体。
一些真菌是通过真菌分泌的真菌毒素(展青霉素,等)的食品中毒的来源。
■成分(粘土和蜂花粉)中的真菌:为了评估蜂花粉/粘土复合物的优点,首先评估每种成分中真菌的数量。
每克粘土具有0个真菌。
每克蜂花粉具有2,900个真菌。
■蜂花粉-粘土复合物的真菌:通过对蜂花粉和粘土进行特定计数,估算了复合物的真菌的数量(通过考虑复合物中的粘土和蜂花粉的比例)(图2)。
因此,根据该估算,每克蜂花粉/粘土复合物应包含967个真菌。而测量表明,每克蜂花粉/粘土复合物包含350个真菌。
蜂花粉/粘土复合物的吸收性能
根据下列步骤测量吸收性能:
1)将过滤器放置在含有水的烧杯中。水逐渐润湿仅稍微浸没在水中的过滤器。
2)轻轻地将粘土(或蜂花粉或复合物)沉积在滤纸上。与滤纸接触的直接沉积物质吸收水。
3)通过毛细管作用,朝向沉积物质的中心逐渐实现了水的吸收。
4)粘土逐渐完全地浸满水。干粘土和湿粘土之间的重量差得出粘土的吸收容量。
在第一阶段,测量每种成分的吸收容量:
-粘土具有吸收其重量的74.38%的容量;
-蜂花粉具有吸收其重量的19.46%的容量。
通过测量的蜂花粉和粘土的特定的吸收容量,通过考虑复合物中的粘土和蜂花粉的比例来估算复合物的吸收容量。因此,根据该估算,蜂花粉-粘土复合物应吸收其重量的56%。目前,测量示出蜂花粉-粘土复合物吸收其重量的65.5%。因此,蜂花粉-粘土复合物的吸收容量比估算值大9.5%(图3)。
通过评估在不同点的曲线斜率,测量每种成分在将蜂花粉和粘土接触水后的不同时刻的吸收速率。因此,粘土的吸收速率大于蜂花粉的吸收速率。通过测量蜂花粉和粘土的特定的吸收速率,通过考虑复合物中粘土和蜂花粉的比例,估算了在不同测量时刻的复合物的吸收容量。该复合物进行的测量表明,蜂花粉/粘土复合物吸水快于从两个成分吸水总和的估算值(在两个小时内,复合物的吸收百分比是两个成分的吸收百分比的总和的2.2倍),且还快于粘土单独的吸水(在两个小时内,复合物的吸收百分比是粘土的吸收百分比的1.8倍)。因此,对于吸收容量,蜂花粉和粘土具有协同效果(图4)。
蜂花粉/粘土复合物的保持能力
为了评估保持能力,使产品(粘土、蜂花粉和复合物)吸收最大量的水。因此,确定对于各种产品的吸水的量(对应于在吸收测量期间所得到的值),然后使产品进行自然脱水(在受控的室温和湿度下),计算失水量(相对于吸收量的百分比)。结果表明:
-蜂花粉比粘土脱水更快;
-粘土完全地(且仅仅)失去其吸收的水,而蜂花粉不仅失去其吸收的水而且还失去包含在蜂花粉颗粒中的水。
在最大吸收后,撤除材料与水的接触。然后在不同时刻测量的失水量,该失水量以最大吸水量的百分比示出。通过测量不同成分的持水能力,估算蜂花粉-粘土复合物的保持能力。复合物采用实验方法得到的测量结果表明:在考虑复合物的组分的对应比例和能力的情况下,该结果比所估算的结果具有更为显著的保持能力。复合物比估计能更好地保持液体(图5)。
在室温下(受控的湿度)超过5天后,除了预期的之外复合物保持其自身重量的15%。蜂花粉和粘土的配制使得可以获得增强保持能力的产品。这些性能表明添加的产品可以保留在在最终产品中。
吸附容量
通过逐渐将显色剂(阳离子)导入粘土的水悬浮液直到饱和来确定吸附容量。进行亚甲基蓝试验:亚甲基蓝是一种被蒙脱石类型的粘土优先吸附的着色的阳离子。该试验是通常用在地质工学中的测试,以用于确定溶胶的清洁度以及溶胶所包含的粘土比例(NF P94-068)。
通过将剂量的亚甲基蓝溶液连续地添加到粘土的水悬浮液中、且通过滤纸上的斑点试验检查有色溶液的吸附,进行试验,以检测游离的着色剂的存在。亚甲基蓝具有被粘土快速吸附的性质。只要亚甲基蓝被吸附,则它不再使溶液中的水着色。这通过将一滴沉积在滤纸上来检查:斑点的中心为亮蓝色(已吸附蓝色的粘土),而斑点晕环保持无色。利用一定剂量的亚甲基蓝,晕环也变得被着色:这是全部粘土已耗尽其吸附容量的信号(饱和)。因此,亚甲基蓝的消耗量为所测试的产品的吸附容量的指示。蓝色值以每克消耗的产品中亚甲基蓝的量表示。
3g粘土(蒙脱石)在20mL软化水中均匀化。执行连续添加1mL的10g/L的亚甲基蓝溶液直到饱和。饱和对应于在滤纸上形成蓝色晕环的时刻;通过每分钟反复斑点试验持续5分钟而不添加任何亚甲基蓝溶液来确认结果。
应该注意,从添加19mL亚甲基蓝溶液起,蓝色晕环略微保持。通过采用该值,可确定粘土的蓝色值为每克粘土63.6mg亚甲基蓝。
3g蜂花粉在20mL软化水中进行均匀化。由于蜂花粉不具有任何吸附性能,故执行连续添加0.1mL的10g/L亚甲基蓝溶液(然后从1mL起,添加1mL)。饱和对应于在滤纸上形成蓝色晕环的时刻;通过每分钟反复该斑点试验持续5分钟而不添加任何亚甲基蓝溶液来确认结果。一旦添加0.1mL的亚甲基蓝溶液,则蓝色晕环略微保持。因此,蜂花粉不具有任何吸附容量(每克蜂花粉0mg亚甲基蓝)。
3g蜂花粉-粘土复合物在20mL软化水中进行均匀化。执行连续添加1mL的10g/L的亚甲基蓝溶液直到饱和。饱和对应于在滤纸上形成蓝色晕环的时刻。通过每分钟反复该斑点试验持续5分钟来确认结果。在添加的亚甲基蓝为12mL时,甚至25分钟后晕环略微保持。这是饱和量。因此,蜂花粉-粘土复合物的蓝色值为每克粘土42.2mg亚甲基蓝(图6)。
这些结果表明,所估算的复合物的吸附容量符合所测量的吸附性能。然而,该测试还表明最初可见的蓝色晕环经过一段时间消失。这表明在蜂花粉和粘土之间发生交换。
粘土和蜂花粉之间的协同作用的平衡
认识到蜂花粉和粘土的固有性能,确定蜂花粉/粘土复合物的下列性能。结果大大超出了估算值且证实了蜂花粉和粘土的组合产生的协同作用。
在下表中示出了全部优点(/估算值):
蜂花粉/粘土复合物的协同作用
由于蜂花粉的性能被保留且使某些功能(例如乳酸酶的功能)被增强,这些性能证实该复合物的极其引人关注的性能。保持能力还允许添加能够被复合物吸附的新的分子/物质。
利用其它类型的粘土(高岭石、伊利石、纤维状矿物)重复实施例1和实施例2。
结果汇总在下表中:
实施例3:明胶胶囊的制备
制备具有硬壳的胶囊或明胶胶囊,该胶囊或明胶胶囊包括预制的壳和半球形的底部,该壳由两个在一端开口的圆柱部分构成。将固体(粉末或颗粒)形式的复合物引入两个部分中的一个部分,然后第二部分安装在第一部分上。由Pfizer出售的胶囊Vcaps可用于该目的。明胶胶囊的表皮是羟丙甲纤维素,其被证实不含淀粉、不含谷蛋白且不含防腐剂。
明胶胶囊包含根据实施例1的500mg的蜂花粉/粘土复合物。示例性地,明胶胶囊可包含:
-粘土:按重量计大于50%;
-蜂花粉:按重量计25%至50%;
-羟丙甲纤维素:按重量计10%至25%;
-二氧化钛:0.1%至1%;
-铜和叶绿酸复合物:按重量计小于0.1%。
所有这些成分符合在食品补充剂的范围内的使用。
实施例4:明胶胶囊的性能
-能量值:129kcal/100g;
-脂质:1.97%;
-碳水化合物:21.4%;
-蛋白质:6.42%;
-灰分:62%。
还确定了物理性能:
-粒径:500μm;
-杂质:无。
得到下列化学性能:
-杀虫剂、重金属、亚硝酸盐和硝酸盐:符合生效的欧盟法规;
-pH:不适用;
-湿度:7.13%;
-水活度wa:在24.4℃下,0.675;
-粘度:不适用;
-密度:不适用。
Claims (11)
1.一种由蜂花粉和粘土组成的复合物,其中,按重量百分比计:
-所述蜂花粉占4%至90%,和
-所述粘土占10%至96%,
并且,其中所述复合物具有小于500μm的粒径、小于15%的湿度和/或小于0.75的水活度(wa)。
2.根据权利要求1所述的复合物,其中所述粘土选自下列类型的粘土:高岭石、蒙脱石、伊利石和绿泥石、或纤维状矿物。
3.根据权利要求1或2所述的复合物,其中所述粘土为蒙脱石。
4.根据权利要求1或2所述的复合物,包括:
-20%至40%的蜂花粉,和
-60%至80%的粘土。
5.一种制备根据权利要求1或2所述的复合物的方法,所述方法包括将蜂花粉和粘土混合的步骤。
6.一种药物组合物,所述药物组合物包括根据权利要求1或2所述的复合物和可选的一种或多种药学上可接受的赋形剂。
7.根据权利要求1至4中任一项所述的复合物在制备用于预防和/或治疗骨质疏松、心血管疾病、癌症、肝脏和代谢紊乱、循环失调、更年期症状、神经系统障碍、肠胃系统障碍、眼部疾病、疲劳、关节障碍、泌尿功能失调、前列腺疾病、营养疾病、皮肤疾病、化妆致皮肤病、无力和易疲劳、恢复期和术后、体液-电解质的失衡、和身体状况的改善的制剂中的用途。
8.根据权利要求7所述的用途,所述制剂用于预防和/或治疗所述前列腺的良性肥大、慢性前列腺炎、前列腺痛或前列腺癌。
9.一种食品组合物,所述食品组合物由权利要求1至4中任一项所述的复合物组成。
10.一种明胶胶囊,所述明胶胶囊包括根据权利要求1至4中任一项所述的由粘土和蜂花粉组成的复合物。
11.一种药物,所述药物包括作为载体的根据权利要求1至4中任一项所述的由粘土和蜂花粉组成的复合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1060511 | 2010-12-14 | ||
FR1060511A FR2968559B1 (fr) | 2010-12-14 | 2010-12-14 | Nouvelles compositions a base d'argile et de beepollen, leur procede de preparation et leurs utilisations en nutrition et en therapeutique |
PCT/EP2011/072756 WO2012080333A1 (fr) | 2010-12-14 | 2011-12-14 | Compositions a base d'argile et de beepollen, leur procede de preparation leurs utilisations en nutrition et en therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103354745A CN103354745A (zh) | 2013-10-16 |
CN103354745B true CN103354745B (zh) | 2017-09-29 |
Family
ID=43881155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180067389.6A Expired - Fee Related CN103354745B (zh) | 2010-12-14 | 2011-12-14 | 基于粘土和蜂花粉的组合物、其制备方法、其营养用途和治疗用途 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9821014B2 (zh) |
EP (1) | EP2651422B1 (zh) |
JP (3) | JP6147193B2 (zh) |
KR (1) | KR20130140093A (zh) |
CN (1) | CN103354745B (zh) |
AU (1) | AU2011343331B2 (zh) |
BR (1) | BR112013016566A2 (zh) |
CA (1) | CA2821219A1 (zh) |
EA (1) | EA029505B1 (zh) |
FR (1) | FR2968559B1 (zh) |
MX (1) | MX346623B (zh) |
RU (1) | RU2622013C2 (zh) |
SG (1) | SG191112A1 (zh) |
WO (1) | WO2012080333A1 (zh) |
ZA (1) | ZA201304301B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2989002B1 (fr) * | 2012-04-10 | 2015-05-15 | Beepratte Lab | Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique |
EP2910119A1 (en) * | 2014-02-21 | 2015-08-26 | Biobest Belgium NV | Pollen compositions and uses thereof |
CN107970438B (zh) * | 2017-11-28 | 2021-08-13 | 镇江市中西医结合医院(镇江市第二人民医院) | 一种神经再生凝胶及其制备方法和应用 |
JP7353101B2 (ja) * | 2019-08-21 | 2023-09-29 | アサヒグループ食品株式会社 | 栄養補助組成物及びその製造方法、動物抽出物又は栄養補助組成物の不快臭の抑制方法、並びに動物抽出物又は栄養補助組成物の不快臭抑制用組成物 |
CN117064996A (zh) * | 2023-10-08 | 2023-11-17 | 江苏鸿祺生物科技有限公司 | 一种保护前列腺的组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101415441A (zh) * | 2006-04-10 | 2009-04-22 | 阿奎坦制药公司 | 愈合组合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59213369A (ja) * | 1983-05-19 | 1984-12-03 | Hiromu Tezuka | 高栄養甘味料 |
EP0191128A1 (en) * | 1985-02-14 | 1986-08-20 | TERAD International, Inc. | Topical preparations for human skin irratations |
US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
CN1185908A (zh) * | 1996-12-27 | 1998-07-01 | 李江 | 一组功能型虫草奶、虫草奶制品及其制备方法 |
RU2113806C1 (ru) * | 1997-02-05 | 1998-06-27 | Ирина Дмитриевна Фадеева | Пищевая биологически активная добавка |
WO2001095728A1 (en) * | 2000-06-13 | 2001-12-20 | Fd Management, Inc. | Cosmetic composition for stressed skin under extreme conditions |
ATE549015T1 (de) * | 2003-10-31 | 2012-03-15 | Hexal Ag | Pharmazeutische wirkstoffhaltige formulierung mit überzug |
RU2260285C1 (ru) * | 2004-03-15 | 2005-09-20 | Государственное учреждение Волгоградский научно-исследовательский технологический институт мясо-молочного скотоводства и переработки продукции животноводства РАСХН | Композиция для получения плавленого сыра |
CN100469253C (zh) * | 2005-12-19 | 2009-03-18 | 余内逊 | 一种微米灰树三花灵芝孢抗肿瘤突变酸奶制备方法 |
EP1979269A4 (en) * | 2005-12-22 | 2013-01-02 | Taiji Biomedical Inc | CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF |
US20080031940A1 (en) * | 2006-08-02 | 2008-02-07 | Al Rodriguez | Quercetin-containing composition, methods of making, and methods of using |
CN1965799A (zh) * | 2006-11-07 | 2007-05-23 | 刘家宝 | 以珍珠为主要成份的日用化妆品及制备方法 |
US20080219939A1 (en) | 2007-03-07 | 2008-09-11 | Grune Guerry L | Sunblock formulations |
CN101711799A (zh) * | 2009-09-08 | 2010-05-26 | 北京资源亚太动物药品有限公司 | 一种用于仔猪接生的外用粉剂 |
-
2010
- 2010-12-14 FR FR1060511A patent/FR2968559B1/fr not_active Expired - Fee Related
-
2011
- 2011-12-14 US US13/993,182 patent/US9821014B2/en not_active Expired - Fee Related
- 2011-12-14 CN CN201180067389.6A patent/CN103354745B/zh not_active Expired - Fee Related
- 2011-12-14 KR KR1020137016221A patent/KR20130140093A/ko not_active Application Discontinuation
- 2011-12-14 JP JP2013543756A patent/JP6147193B2/ja not_active Expired - Fee Related
- 2011-12-14 AU AU2011343331A patent/AU2011343331B2/en not_active Ceased
- 2011-12-14 WO PCT/EP2011/072756 patent/WO2012080333A1/fr active Application Filing
- 2011-12-14 EP EP11799669.4A patent/EP2651422B1/fr not_active Not-in-force
- 2011-12-14 SG SG2013045075A patent/SG191112A1/en unknown
- 2011-12-14 MX MX2013006741A patent/MX346623B/es active IP Right Grant
- 2011-12-14 BR BR112013016566A patent/BR112013016566A2/pt not_active Application Discontinuation
- 2011-12-14 CA CA2821219A patent/CA2821219A1/fr not_active Abandoned
- 2011-12-14 RU RU2013132218A patent/RU2622013C2/ru not_active IP Right Cessation
- 2011-12-14 EA EA201390867A patent/EA029505B1/ru not_active IP Right Cessation
-
2013
- 2013-06-11 ZA ZA2013/04301A patent/ZA201304301B/en unknown
-
2016
- 2016-06-02 JP JP2016110719A patent/JP2016164196A/ja not_active Withdrawn
-
2017
- 2017-04-13 JP JP2017079810A patent/JP2017158563A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101415441A (zh) * | 2006-04-10 | 2009-04-22 | 阿奎坦制药公司 | 愈合组合物 |
Also Published As
Publication number | Publication date |
---|---|
EP2651422A1 (fr) | 2013-10-23 |
RU2013132218A (ru) | 2015-01-20 |
RU2622013C2 (ru) | 2017-06-08 |
MX346623B (es) | 2017-03-27 |
US20130287855A1 (en) | 2013-10-31 |
KR20130140093A (ko) | 2013-12-23 |
WO2012080333A1 (fr) | 2012-06-21 |
ZA201304301B (en) | 2014-03-26 |
BR112013016566A2 (pt) | 2016-09-27 |
JP2014501238A (ja) | 2014-01-20 |
CN103354745A (zh) | 2013-10-16 |
JP6147193B2 (ja) | 2017-06-14 |
AU2011343331A8 (en) | 2015-07-30 |
SG191112A1 (en) | 2013-07-31 |
FR2968559A1 (fr) | 2012-06-15 |
FR2968559B1 (fr) | 2012-12-28 |
JP2016164196A (ja) | 2016-09-08 |
EA029505B1 (ru) | 2018-04-30 |
EA201390867A1 (ru) | 2013-11-29 |
EP2651422B1 (fr) | 2017-10-18 |
AU2011343331A1 (en) | 2013-07-11 |
US9821014B2 (en) | 2017-11-21 |
MX2013006741A (es) | 2013-12-06 |
JP2017158563A (ja) | 2017-09-14 |
AU2011343331B2 (en) | 2016-11-03 |
CA2821219A1 (fr) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103354745B (zh) | 基于粘土和蜂花粉的组合物、其制备方法、其营养用途和治疗用途 | |
AU2016262125B2 (en) | Amino acid supplementation | |
JP2001238641A5 (zh) | ||
CN106552105A (zh) | 一种增强免疫力的泡腾片及其制备方法 | |
CN101569410A (zh) | 肿瘤患者用的特膳营养食品 | |
CN109222100A (zh) | 一种人参蛹虫草组合物、人参蛹虫草压片糖果及其制备方法 | |
JP2002034592A (ja) | 体内に吸収されやすい蛋白化−亜鉛の製造方法 | |
CN109329947A (zh) | 具有改善睡眠通便美白功能的胶原蛋白肽直饮粉及其制备方法 | |
CN102934719A (zh) | 一种银杏苦荞茶及其制备工艺 | |
EP1352569A1 (en) | Foods containing young wheat leaf powder | |
CN101032523B (zh) | 一种蜂王浆酸钙及其制备方法 | |
CN109090319A (zh) | 乳矿物盐压片糖果 | |
JP2007297312A (ja) | 生命機能賦活剤の製造方法 | |
CN107510701B (zh) | 一种儿童补铁与维生素的组合物及其制备方法和应用 | |
KR20200107809A (ko) | 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제 | |
KR20190134561A (ko) | 비 가열처리 공법을 이용한 고로쇠 과립 및 이의 제조방법 | |
CN101171037A (zh) | 营养补充剂透过粘膜吸收的可食用薄膜 | |
CN109418804A (zh) | 一种海藻咀嚼片及其制备方法 | |
CN104606279B (zh) | 一种多孔纳米生物多元钙及其应用 | |
EP3441062A1 (en) | Seawater and salt powder balancing formulations and nutritional and pharmaceutical compositions | |
WO2024042122A1 (en) | Oral formulations comprising porous silica particles and medical uses thereof | |
CN205337500U (zh) | 含有控制肥胖症成分的口含锭 | |
KR20200141012A (ko) | 남성 성기능 장애의 예방 또는 치료용 약학적 조성물 | |
CN118749647A (zh) | 一种中药养生汤吸收促进剂及中药养生汤与其制备工艺 | |
WO2002074104A1 (fr) | Alitements contenant de la poudre de feuille de ble jeune |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170929 Termination date: 20181214 |
|
CF01 | Termination of patent right due to non-payment of annual fee |